Accession Number:



Molecular Innovations Toward Theranostics of Aggressive Prostate Cancer

Descriptive Note:

Technical Report,01 Sep 2012,31 Aug 2017

Corporate Author:

University of Texas Southwestern Medical Center Dallas United States

Personal Author(s):

Report Date:


Pagination or Media Count:



Conventional chemotherapy with cell killing en mass often targets mitotic cells with less specificity, which likely leads to undesirable side effect. Knowing specific molecular defects in cancer cells has led to discover new chemotherapeutic agents. Thus, combined agents targeting different defected pathways in cancer cells have a better chance to eradicate tumor completely. Thus, to achieve a cure, a comprehensive targeting strategy needs to be implemented. In addition, improvedmethods for monitoring drug delivery and tumor response in a nearly real-time manner should offer a safe and effective treatment. This project carried out by a team of chemist, radiologist, and molecular tumor biologist is to develop a novel drug delivery system with new small molecular therapeutic agents assisted with new imaging probe is expect to bring a new frontier for prostate cancer PCa management. Our objective is to develop dendrimer-based theranostic agent with prostate cancer specificity and positron emission tomography imaging capability that can prevent the early onset of PCa metastasis or delay the progression of metastasis. The mission of my project is to design small peptide derived from tumor suppressor DAB2 family as therapeutic agent and examine its biology activities.

Subject Categories:

  • Medicine and Medical Research
  • Biochemistry
  • Pharmacology

Distribution Statement: